Biomerica, Inc. (BMRA) 股票分析

公司概述

Biomerica, Inc. operates as a biomedical technology entity focused on the development, patenting, manufacturing, and marketing of diagnostic and therapeutic products designed to detect and treat various medical conditions globally. The company's specific diagnostic test kits are engineered to analyze biological samples such as blood and urine, as well as nasal samples, facilitating precise medical analysis. This enterprise functions within the Healthcare sector, specifically targeting the Medical Devices industry, which encompasses a wide range of technologies used for patient diagnosis and treatment. In terms of scale, the company holds a market capitalization of $6.64M with an annual trailing twelve-month revenue of $4.46M and employs a workforce of 53 individuals. These valuation and revenue figures indicate that Biomerica, Inc. operates as a small-cap entity with a relatively modest revenue base, suggesting a niche market position rather than broad-scale dominance in the medical device landscape.

财务健康

The company reported a trailing twelve-month revenue of $4.46M alongside a net income of $-4,025,000 and an EBITDA of $-5,179,000, revealing a significant divergence between top-line sales and bottom-line profitability that highlights a heavy cost structure or substantial operational expenses. The free cash flow stands at $-1,701,375, which indicates a current state of negative cash generation that constrains the company's immediate financial flexibility and ability to fund operations without external capital injections. Margin analysis shows a gross margin of 5.6%, an operating margin of -113.5%, and a profit margin of -90.3%, where the negative operating and profit margins suggest that operating expenses are exceeding the revenue generated, while the low gross margin points to high production or procurement costs relative to sales prices. Regarding the balance sheet, the company holds $2.54M in cash against $284,000 in debt, resulting in a debt-to-equity ratio of 6.40, which technically indicates a leveraged position despite the absolute debt amount being small, as the ratio is inflated by the negative equity base implied by the losses. However, the current ratio of 3.25 demonstrates robust short-term liquidity, indicating that the company possesses more than three times the current assets necessary to cover its current liabilities. Return on Equity is recorded at -84.3% and Return on Assets at -49.4%, metrics that reveal that management has not yet achieved profitability, resulting in negative returns on the capital deployed by shareholders and invested in assets.

估值评估

The valuation metrics present a complex picture with a trailing P/E ratio of N/A due to losses, while the forward P/E is listed at 5.64, implying that the market anticipates a significant turnaround in earnings to justify current share prices in the near future. The price-to-book ratio is 1.46, suggesting that the market values the company at a 46% premium over its book value, which may reflect potential future growth options or intangible assets not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 1.49 and an EV/EBITDA of -0.85, where the negative EV/EBITDA confirms the company's unprofitable status but allows analysts to value the firm based on enterprise value relative to operating performance. In terms of price action, the stock trades between a 52-week high of $4.88 and a 52-week low of $1.87, with the current price situated within this range and reflecting the volatility typical of small-cap biotech stocks. The beta value of 0.20 indicates that the stock exhibits low volatility relative to the broader market, moving significantly less than the overall index, which offers a degree of price stability often associated with smaller, less liquid equities.

Growth & Income

Revenue growth year-over-year is recorded at -26.0%, while earnings growth is N/A due to the company's lack of profitability, indicating that the business is currently contracting or losing revenue rather than expanding. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, implying that the company reinvests all available capital, however limited, into research, development, and operational expenses rather than paying dividends. The overall growth and income profile for Biomerica, Inc. is characterized by negative revenue expansion and a complete absence of dividend income, reflecting the early-stage or distressed nature of the business model where capital preservation and operational restructuring likely take precedence over shareholder returns.